Manufacturer: Alkem
Pharmaceutical name: Clindamycin
Pack: 1 tube (15 g (1%))
Clindac A Gel phosphate topical gel, 1%, is a topical antibiotic that has been approved for treating acne vulgaris. This gel is classified as a lincosamide antibiotic. Clindamycin, the active ingredient, is thought to destroy acne-related bacteria by hindering protein synthesis at the ribosomal level, where proteins are produced.
The phrase "acne vulgaris" refers to the more prevalent type of acne, which includes both non-inflammatory and slightly inflammatory lesions. The more severe variant of acne features nodules. In the United States, nearly 17 million individuals are affected by acne, making it the most common skin condition. While acne typically does not pose a serious health risk, severe cases can result in disfiguring permanent scars, which can be distressing for those who experience this condition.
Side effects linked to Clindac A Gel phosphate gel include skin itching and peeling. Instances of diarrhea, bloody diarrhea, and colitis have been noted as side effects in patients treated with oral and intravenous forms of Clindac A Gel, and these effects have been reported infrequently with the topical formulation of clindamycin. Additionally, abdominal pain, gastrointestinal issues, and gram-negative folliculitis (a bacterial infection causing inflammation of hair follicles) have been documented in connection with the topical versions of Clindac-A Gel.
Although Clindac A Gel is inactive when tested in vitro, it rapidly undergoes hydrolysis to convert into clindamycin, which possesses antibacterial properties. Clindamycin works by inhibiting bacterial protein synthesis at the ribosomal level, binding to the 50S ribosomal subunit and disrupting the initiation of peptide chain formation.